NZYM B Novozymes A/S Class B

Resolutions from the Annual General Meeting 2026

Resolutions from the Annual General Meeting 2026

Today, the Annual General Meeting of Novonesis (Novozymes A/S) was conducted.

The following resolutions were made:

  • Approval of the audited Annual Report for 2025
  • Approval of distribution of profit with payment of an ordinary dividend of DKK 4.25 (corresponding to approximately EUR 0.57) per A and B share. In addition to this year-end dividend, an interim dividend of DKK 2.25 (corresponding to approximately EUR 0.3) was disbursed on August 27, 2025
  • Approval of the Remuneration Report for 2025 (advisory vote)
  • Approval of the remuneration of members of the Board of Directors for 2026
  • Re-election of Cornelis (Cees) de Jong as Chair of the Board of Directors
  • Re-election of Heine Dalsgaard as Vice Chair of the Boad of Directors
  • Re-election of Lise Kaae, Monila Kothari, Kasim Kutay, Kevin Lane, Morten Otto Alexander Sommer, and Kim Stratton as members of the Board of Directors
  • Re-election of EY Godkendt Revisionspartnerselskab as the company’s auditors in respect of statutory financial and sustainability reporting
  • Approval to renew the authorizations to the Board of Directors to implement capital increases
  • Approval to renew the authorization to the Board of Directors to acquire treasury shares
  • Approval of the authorization to the Board of Directors to distribute extraordinary dividends
  • The shareholder proposal was withdrawn



Composition of the Board of Directors and its committees



After the Annual General Meeting, the Board of Directors held a board meeting to appoint members of its committees.

The Board of Directors, including its committees, continues to be composed as follows:

  • Cees (Cornelis) de Jong (Chair of the Board, chair of the Nomination and Remuneration Committee and member of the Audit Committee)
  • Heine Dalsgaard (Vice Chair of the Board and member of the Audit Committee)
  • Robert Nøddeskov Jensen (employee representative)
  • Lise Kaae (chair of the Audit Committee)
  • Monila Kothari (member of the Innovation Committee)
  • Kasim Kutay (member of the Nomination and Remuneration Committee)
  • Lars Bo Køppler (employee representative and member of the Nomination and Remuneration Committee)
  • Kevin Lane (member of the Innovation Committee)
  • Preben Nielsen (employee representative and member of the Innovation Committee)
  • Frederikke Rose Spenner (employee representative)
  • Morten Otto Alexander Sommer (chair of the Innovation Committee)
  • Kim Stratton (member of the Nomination and Remuneration Committee)

For further information on the members of the Board of Directors, please go to

Attachment



EN
23/03/2026

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Novozymes A/S Class B

 PRESS RELEASE

Resolutions from the Annual General Meeting 2026

Resolutions from the Annual General Meeting 2026 Today, the Annual General Meeting of Novonesis (Novozymes A/S) was conducted. The following resolutions were made: Approval of the audited Annual Report for 2025Approval of distribution of profit with payment of an ordinary dividend of DKK 4.25 (corresponding to approximately EUR 0.57) per A and B share. In addition to this year-end dividend, an interim dividend of DKK 2.25 (corresponding to approximately EUR 0.3) was disbursed on August 27, 2025Approval of the Remuneration Report for 2025 (advisory vote)Approval of the remuneration of membe...

 PRESS RELEASE

Trading by management and close relations of management

Trading by management and close relations of management In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the “Market Abuse Regulation”) and commission delegated regulation (EU) 1052/2016of 8 March 2016, Novonesis reports the following transactions under ISIN DK0060336014, Novonesis (Novozymes) B shares under the symbol NSIS B. Please read the full announcement in PDF. Attachment

 PRESS RELEASE

Novonesis issues EUR 1.7 billion in bonds to refinance bridge facility

Novonesis issues EUR 1.7 billion in bonds to refinance bridge facility COPENHAGEN, Denmark – March 16, 2026. Novonesis has completed a EUR 1.7 billion bond issuance, with significant interest from a broad group of investors. The transaction was primarily undertaken to refinance the bridge facility related to Novonesis’ purchase of the dsm firmenich’s part in the Feed Enzyme Alliance, closed in June 2025. The acquisition gives Novonesis full control of the alliance’s sales and distribution, strengthening the company’s position across the animal biosolutions value chain. Rainer Lehmann, CFO...

 PRESS RELEASE

Novonesis issues EUR 1.7 billion senior unsecured notes

Novonesis issues EUR 1.7 billion senior unsecured notes On March 12, 2026, Novonesis, through Novozymes A/S, successfully priced and closed an aggregate principal amount of EUR 1.7 billion senior unsecured notes (the "Notes"). The issuance was completed under the newly established EUR 4 billion Euro Medium Term Note (EMTN) Programme, dated March 10, 2026. The Notes will be issued on March 19, 2026, and listed on the Luxembourg Stock Exchange. This inaugural issuance consists of three tranches with maturities ranging from 4 to 11 years and fixed interest rates ranging from 3.25% to 4.00%. ...

 PRESS RELEASE

Trading by management and close relations of management

Trading by management and close relations of management In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the “Market Abuse Regulation”) and commission delegated regulation (EU) 1052/2016of 8 March 2016, Novonesis reports the following transactions under ISIN DK0060336014, Novonesis (Novozymes) B shares under the symbol NSIS B. Please read the full announcement in PDF. Attachment

ResearchPool Subscriptions

Get the most out of your insights

Get in touch